MedTrace Logo

Prospective Real-world Registry Describing Treatment Regimens

NCT03942913 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 573

Last updated 2022-08-16

No results posted yet for this study

Summary

This study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.

Conditions

  • Subject Under Anticoagulant

Interventions

OTHER

an observational study

this study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.

Sponsors & Collaborators

  • Assistance Publique Hopitaux De Marseille

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-10
Primary Completion
2023-08-01
Completion
2023-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03942913 on ClinicalTrials.gov